Market Cap (In USD)
904.76 Million
Revenue (In USD)
17.48 Million
Net Income (In USD)
-78.5 Million
Avg. Volume
1.25 Million
- Currency
- USD
- Country
- Healthcare
- Open
- -
- Prev. Close
- -
- Day Range
- -
- Year Range
- 8.26-16.99
- PE
- -
- EPS
- -
- Beta Value
- 0.205
- ISIN
- US53635D2027
- CUSIP
- 53635D202
- CIK
- 1819576
- Shares
- -
- Earnings Annoncement
- -
Company Profile
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Dr. Roger A. Jeffs Ph.D.
- Employee Count
- -
- Website
- https://www.liquidia.com
- Ipo Date
- 2018-07-26
- Details
- Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension. It also distributes generic treprostinil injection in the United States. Liquidia Corporation was founded in 2004 and is headquartered in Morrisville, North Carolina.
More Stocks
-
3030Test Research, Inc.
3030
-
9908
-
RICA
-
DHG
-
0IRKAltarea SCA
0IRK
-
IHGP
-
CPA
-
3029